Key regions: United Kingdom, Brazil, Europe, France, Canada
Anti-Fibrinolytic Drugs are increasingly becoming popular in Uganda due to the growing awareness of the drugs and their benefits.
Customer preferences: Anti-Fibrinolytic Drugs are used to prevent excessive bleeding during surgical procedures and are in high demand in Uganda due to the high prevalence of infectious diseases that require surgical intervention. Patients prefer these drugs as they aid in reducing the risk of blood loss during surgery, which in turn reduces the need for blood transfusions.
Trends in the market: The Anti-Fibrinolytic Drugs market in Uganda is witnessing a steady growth due to the increasing number of surgical procedures being performed in the country. The rise in the number of road accidents and infectious diseases has led to an increase in the number of surgical interventions in Uganda. The demand for these drugs is expected to rise in the coming years as the government and private healthcare institutions continue to invest in the healthcare sector.
Local special circumstances: Uganda is a low-income country with a high burden of infectious diseases, including HIV/AIDS, malaria, and tuberculosis. This has led to an increase in the number of surgical interventions being performed in the country, which in turn has led to an increase in the demand for Anti-Fibrinolytic Drugs. The government has also been investing in the healthcare sector, which has led to an increase in the availability of these drugs in the country.
Underlying macroeconomic factors: The healthcare sector in Uganda is growing, and the government has been investing in the sector to improve the quality of healthcare services in the country. The government has also been encouraging private investment in the healthcare sector, which has led to an increase in the number of private healthcare institutions in the country. The rise in the number of private healthcare institutions has led to an increase in the availability of Anti-Fibrinolytic Drugs in the country. Additionally, the rise in the number of surgical interventions being performed in the country has led to an increase in the demand for these drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
